Literature DB >> 217544

Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells.

D A Thorley-Lawson.   

Abstract

A rabbit antiserum has been prepared against the B95-8 transforming strain of EBV. The antiserum has a high virus neutralizing titer (approximately 1:1000) against both the marmoset B95-8 EBV and the human P3HR-1 EBV. The neutralizing antibodies may be absorbed completely with EBV producer cell lines, but not with nonproducer cell lines or producer cell lines treated with phosphonoacetic acid (PAA) so as to be nonproducer. After repeated absorption with PAA-treated B95-8, the serum remains reactive with the membranes of producer cell lines as judged by immunofluorescence or the 125I--Staphylococcal protein A radioimmunoassay. Thus the neutralizing antigens are expressed on the membranes of producer cell lines and may be purified from this source using the serum and 125I--Staph A binding as an assay. The ability of the serum to differentiate between producer and nonproducer cells by means of cell surface determinants has been exploited to achieve a separation of these two populations from the same culture. Immunoprecipitation by the protein A technique shows that the serum recognizes two polypeptides from producer cells of approximate molecular weights 150,000 and 75,000.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 217544     DOI: 10.1016/0092-8674(79)90185-5

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  17 in total

1.  Regulation of two alcohol dehydrogenases in Aspergillus nidulans.

Authors:  H M Sealy-Lewis; R A Lockington
Journal:  Curr Genet       Date:  1984-05       Impact factor: 3.886

2.  Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors:  Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

3.  Identification of the Epstein-Barr virus gp85 gene.

Authors:  T Heineman; M Gong; J Sample; E Kieff
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

4.  Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences.

Authors:  C M Edson; D A Thorley-Lawson
Journal:  J Virol       Date:  1981-07       Impact factor: 5.103

5.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

6.  Filamentous structures associated with Epstein-Barr virus-infected cells.

Authors:  C L Moore; J D Griffith; J E Shaw
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

7.  Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.

Authors:  D A Thorley-Lawson; C A Poodry
Journal:  J Virol       Date:  1982-08       Impact factor: 5.103

8.  An 88,000-Mr Giardia lamblia surface protein which is immunogenic in humans.

Authors:  C M Edson; M J Farthing; D A Thorley-Lawson; G T Keusch
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

9.  Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.

Authors:  G R Nemerow; F C Jensen; N R Cooper
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

10.  Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.

Authors:  J R North; A J Morgan; J L Thompson; M A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.